On September 9, 2020 MilliporeSigma reported a $65 million expansion of its HPAPI and ADC manufacturing capabilities and capacity at its facility near Madison, Wisconsin (Press release, MilliporeSigma, SEP 9, 2020, View Source [SID1234564898]). This investment will allow large-scale manufacturing of increasingly potent compounds that have the potential to treat cancer. Completion is expected by mid-2022 and should add approximately 50 full-time jobs starting in 2021.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
MilliporeSigma is expanding its ADC manufacturing capabilities. ADCs are an emerging class of medicines designed for high-specificity targeting and destruction of cancer cells, while preserving healthy ones.
"ADCs have posted incredible growth over the last decade and regulatory agencies’ approval in recent years demonstrate their promise as a targeted therapy," said Andrew Bulpin, head of Process Solutions at MilliporeSigma. "With more than 35 years of experience in this space, we have been a frontrunner in the development and manufacturing of biologics, conjugation processes and small molecules. This investment underscores our commitment to working with innovators to bring new treatments to patients quickly and more efficiently."
MilliporeSigma’s new 70,000-square-foot commercial building will be one of the largest dedicated HPAPI manufacturing facilities specifically designed to handle single-digit nanogram occupational exposure limit materials. The facility will incorporate containment areas to produce next-generation linker and payload materials for ADCs. The project is an addition to the company’s Madison campus, which was the first commercial ADC facility in North America designed to handle highly active materials. It will join MilliporeSigma’s established campus in St. Louis, Missouri, which specializes in ADC bio-conjugation, active pharmaceutical ingredients, excipient and adjuvants manufacturing.
ADCs are an emerging class of medicines designed for high-specificity targeting and destruction of cancer cells, while preserving healthy cells. There are now only nine ADCs approved globally. However, the ADC industry is delivering strong growth and is expected to reach $15 billion by 20301.
While ADCs can provide many benefits compared with other therapeutic options, they also present a unique set of challenges. Their development is complex, necessitating stringent containment infrastructure, and their structural exceptionality requires expertise in a number of different technologies for small and large molecules, as well as analytical capabilities. Due to these challenges, more than 70 percent of ADC projects are outsourced to contract development and manufacturing organizations2.
With more than 35 years of experience in the development and manufacturing of small molecules, biologics and ADC technologies, MilliporeSigma offers extensive experience in both clinical and commercial manufacturing. The company’s comprehensive service portfolio combines the steps of drug development and production — from pre-clinical to commercial — from a single source. This consolidation helps reduce risk and streamlines the process of getting therapies to patients faster.
Follow MilliporeSigma on Twitter @MilliporeSigma, on Facebook @MilliporeSigma and on LinkedIn.
All Merck KGaA, Darmstadt, Germany news releases are distributed by email at the same time they become available on the EMD Group website. In case you are a resident of the U.S. or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.